AstraZeneca Invests $100 Million To Expand Shanghai Site In Move To Capture Larger Share Of Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - AstraZeneca is investing $100 million to expand its current site in the Shanghai Zhangjiang Hi-Tech Park to strengthen its China headquarters and beef up marketing, R&D and academic training
You may also be interested in...
Growth Strategy: AstraZeneca Launches APAC Headquarters In Shanghai
The second largest pharma company in China has opened a new Asia-Pacific headquarters in Shanghai’s Zhangjiang Hi-tech Park as it looks to jumpstart growth that has recently slowed.
AstraZeneca R&D VP Steve Yang On Building R&D Success In Emerging Markets: An Interview With PharmAsia News (Part 1 of 2)
The global pharma market in the next five years is expected to grow 3-6% compared to 6.2% in the past five years, while emerging markets will drive major growth and will hold 28% of global spending on medicines by 2015.
AstraZeneca R&D VP Steve Yang On Building R&D Success In Emerging Markets: An Interview With PharmAsia News (Part 1 of 2)
The global pharma market in the next five years is expected to grow 3-6% compared to 6.2% in the past five years, while emerging markets will drive major growth and will hold 28% of global spending on medicines by 2015.